A GLP-1 and GIP dual agonist is a single molecule designed to activate two incretin receptors at once: the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. Incretins are gut-derived hormones that regulate insulin secretion and glucose metabolism, and the two receptors mediate overlapping but distinct effects. The dual-agonist approach — combining both activities in one peptide — has been one of the most significant developments in metabolic peptide research, with tirzepatide as the leading example. This guide explains what GLP-1 and GIP are, what each receptor contributes, why activating both together is of research interest, and how the dual-agonist concept works.
GLP-1 and GIP at a glance
| Property | GLP-1 | GIP |
|---|---|---|
| Full name | Glucagon-like peptide-1 | Glucose-dependent insulinotropic polypeptide |
| Class | Incretin hormone | Incretin hormone |
| Released from | Intestinal L-cells | Intestinal K-cells |
| Insulin effect | Glucose-dependent insulin secretion | Glucose-dependent insulin secretion |
| Other documented roles | Slowed gastric emptying, appetite signalling | Lipid metabolism, adipose tissue signalling |
| Dual agonist example | Tirzepatide (activates both receptors) | |
Trutide supplies research-grade Tirzepatide — a GLP-1 and GIP dual agonist — at ≥98% HPLC purity, independently tested by Janoshik Analytical.
What incretins are
Incretins are hormones released from the gut in response to food intake that act to regulate blood glucose, primarily by stimulating insulin secretion from the pancreas. The defining feature of incretin action is that it is glucose-dependent — incretins enhance insulin secretion when blood glucose is elevated, but their insulinotropic effect diminishes as glucose falls toward normal levels. This glucose-dependence is a central concept in incretin research.
The two principal incretin hormones are GLP-1 and GIP. Together they are responsible for the “incretin effect” — the observation that oral glucose produces a substantially greater insulin response than the same amount of glucose given intravenously, because the oral route triggers incretin release from the gut. Both hormones are rapidly degraded in the body by the enzyme dipeptidyl peptidase-4 (DPP-4), which is why synthetic incretin receptor agonists are engineered for resistance to this degradation.
What the GLP-1 receptor does
The GLP-1 receptor is the more extensively studied of the two incretin receptors. Activation of the GLP-1 receptor has several documented effects in published research: glucose-dependent stimulation of insulin secretion, suppression of glucagon release (the hormone that raises blood glucose), slowing of gastric emptying, and effects on appetite signalling through central nervous system pathways. The breadth of these effects is why GLP-1 receptor agonists have been such a major focus of metabolic research, and why GLP-1 was the first incretin pathway to be developed into receptor agonists.
What the GIP receptor adds
GIP is the other major incretin, and historically it received less research attention than GLP-1. Like GLP-1, the GIP receptor mediates glucose-dependent insulin secretion. But GIP also has documented roles that differ from GLP-1 — particularly in lipid metabolism and adipose tissue signalling, where GIP receptor activation has effects that GLP-1 does not replicate.
The research rationale for adding GIP receptor activation to GLP-1 receptor activation rests on this complementarity. The two incretin receptors both enhance glucose-dependent insulin secretion, so activating both can produce a greater combined effect on that shared endpoint. But GIP also engages metabolic pathways — especially around lipid handling — that GLP-1 alone does not, broadening the overall metabolic profile. The combination is therefore studied as more than simply a doubling of incretin signalling; it is an attempt to engage two related but non-identical metabolic pathways simultaneously.
The dual-agonist concept
A dual agonist is a single engineered molecule that activates two receptors. Rather than administering two separate compounds, the dual-agonist approach designs one peptide whose structure allows it to bind and activate both the GLP-1 and GIP receptors.
Tirzepatide is the leading example. It is a synthetic peptide engineered to activate both incretin receptors, and it incorporates a fatty acid chain (acylation) that allows it to bind albumin and resist DPP-4 degradation — extending its half-life to permit once-weekly administration in research protocols. The single-molecule approach has practical advantages over co-administering two separate agonists: a fixed, consistent ratio of the two activities, a single pharmacokinetic profile, and simpler handling. For a full overview of tirzepatide specifically, see our Tirzepatide research guide.
Beyond dual: triple agonists
The dual-agonist concept has been extended further. Triple agonists add a third receptor target — the glucagon receptor — to the GLP-1 and GIP combination. Retatrutide is the leading example of this triple-agonist class, engaging all three receptors in a single molecule. The addition of glucagon receptor activity is intended to engage energy-expenditure and hepatic metabolic pathways that the dual incretin combination does not. For detail on the triple-agonist approach and what the glucagon receptor adds, see our guide on GLP-1, GIP and glucagon receptor agonists.
Frequently asked questions
What is a GLP-1 and GIP dual agonist?
It is a single engineered peptide that activates two incretin receptors — the GLP-1 receptor and the GIP receptor — at the same time. Tirzepatide is the leading example. The approach combines two related metabolic pathways in one molecule rather than using two separate compounds.
What is the difference between GLP-1 and GIP?
Both are incretin hormones that stimulate glucose-dependent insulin secretion. GLP-1 also suppresses glucagon, slows gastric emptying, and affects appetite signalling. GIP has additional documented roles in lipid metabolism and adipose tissue signalling that GLP-1 does not replicate. They are complementary rather than identical.
Why activate both receptors instead of just GLP-1?
Both receptors enhance glucose-dependent insulin secretion, so activating both can produce a greater combined effect on that shared endpoint. GIP also engages metabolic pathways — particularly around lipid handling — that GLP-1 alone does not, broadening the overall metabolic profile beyond what single GLP-1 activation achieves.
What does “glucose-dependent” mean?
It means the insulin-stimulating effect of incretins depends on blood glucose being elevated. The effect is strong when glucose is high and diminishes as glucose returns toward normal. This glucose-dependence is a defining feature of incretin biology.
Which is the leading dual agonist?
Tirzepatide is the leading GLP-1/GIP dual agonist. It is engineered to activate both incretin receptors and is acylated for an extended half-life supporting once-weekly administration in research protocols.
How does a dual agonist differ from a triple agonist?
A dual agonist (e.g. tirzepatide) activates two receptors — GLP-1 and GIP. A triple agonist (e.g. retatrutide) adds a third target, the glucagon receptor. The glucagon receptor activity is intended to engage energy-expenditure and hepatic pathways beyond the incretin effects of the dual combination.
Can dual agonists be used in humans?
No. Tirzepatide supplied by Trutide is intended strictly for in vitro laboratory and scientific research. It is not for human or veterinary consumption, clinical use, or self-administration.
Further reading
For a full overview of the leading dual agonist — including mechanism, pharmacokinetics, published research, and handling — see our Tirzepatide research guide. For the triple-agonist extension of this concept, see our guide on GLP-1, GIP and glucagon receptor agonists.
Trutide supplies research-grade Tirzepatide at ≥98% HPLC purity, independently tested by Janoshik Analytical. You will also need bacteriostatic water for reconstitution.
Research use only. This article is intended for qualified researchers only. All information is provided for educational and scientific reference purposes. Nothing in this article constitutes medical advice. Tirzepatide supplied by Trutide is strictly for in vitro laboratory research and is not for human or veterinary use.
References
- Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Molecular Metabolism. 2018;18:3-14. doi:10.1016/j.molmet.2018.09.009
- Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes, Obesity and Metabolism. 2018;20(Suppl 1):5-21. doi:10.1111/dom.13129
- Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021;385(6):503-515. doi:10.1056/NEJMoa2107519
- Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131-2157. doi:10.1053/j.gastro.2007.03.054
- Min T, Bain SC. The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials. Diabetes Therapy. 2021;12(1):143-157. doi:10.1007/s13300-020-00981-0
Last updated: 7 June 2026